全文获取类型
收费全文 | 5144篇 |
免费 | 486篇 |
国内免费 | 75篇 |
专业分类
耳鼻咽喉 | 33篇 |
儿科学 | 135篇 |
妇产科学 | 111篇 |
基础医学 | 590篇 |
口腔科学 | 94篇 |
临床医学 | 495篇 |
内科学 | 1017篇 |
皮肤病学 | 68篇 |
神经病学 | 252篇 |
特种医学 | 379篇 |
外科学 | 701篇 |
综合类 | 190篇 |
预防医学 | 471篇 |
眼科学 | 190篇 |
药学 | 407篇 |
中国医学 | 96篇 |
肿瘤学 | 476篇 |
出版年
2023年 | 44篇 |
2022年 | 59篇 |
2021年 | 104篇 |
2020年 | 67篇 |
2019年 | 111篇 |
2018年 | 103篇 |
2017年 | 93篇 |
2016年 | 93篇 |
2015年 | 135篇 |
2014年 | 163篇 |
2013年 | 196篇 |
2012年 | 269篇 |
2011年 | 270篇 |
2010年 | 188篇 |
2009年 | 187篇 |
2008年 | 271篇 |
2007年 | 293篇 |
2006年 | 244篇 |
2005年 | 280篇 |
2004年 | 209篇 |
2003年 | 215篇 |
2002年 | 170篇 |
2001年 | 136篇 |
2000年 | 126篇 |
1999年 | 136篇 |
1998年 | 100篇 |
1997年 | 96篇 |
1996年 | 84篇 |
1995年 | 79篇 |
1994年 | 64篇 |
1993年 | 63篇 |
1992年 | 100篇 |
1991年 | 90篇 |
1990年 | 84篇 |
1989年 | 97篇 |
1988年 | 97篇 |
1987年 | 92篇 |
1986年 | 62篇 |
1985年 | 61篇 |
1984年 | 37篇 |
1983年 | 33篇 |
1982年 | 41篇 |
1981年 | 35篇 |
1980年 | 29篇 |
1979年 | 29篇 |
1978年 | 20篇 |
1977年 | 23篇 |
1976年 | 27篇 |
1975年 | 15篇 |
1972年 | 12篇 |
排序方式: 共有5705条查询结果,搜索用时 9 毫秒
41.
Potential cancer therapy with the fragile histidine triad gene: review of the preclinical studies. 总被引:9,自引:0,他引:9
CONTEXT: The fragile histidine triad gene (FHIT) encompasses a human common fragile site, FRA3B, that is susceptible to environmental carcinogens. Deletion and inactivation of FHIT have been seen in a number of human premalignant and malignant lesions. OBJECTIVE: To review and evaluate preclinical studies of cancer therapy using the FHIT tumor suppressor gene and related studies involving Fhit protein expression. DATA SOURCES: A MEDLINE search of articles published from 1996 to June 2001 was performed; article reference lists were used to retrieve additional relevant articles. STUDY SELECTION: Immunohistochemical studies of primary tumors or relevant lesions were selected to evaluate Fhit expression in premalignant or malignant stages. Preclinical studies on antitumorigenic or therapeutic introduction of FHIT were reviewed for the effects of exogenous Fhit expression. For the immunohistochemical analyses, 26 studies were included that analyzed at least 15 cases of a single type of tumor. For precancerous lesions, 9 studies were included that analyzed at least 4 cases. For studies of FHIT introduction, 9 published studies were included. DATA EXTRACTION: Using primary data from each of the studies, we assessed the rationale and potential contribution of FHIT cancer therapy. Data was independently abstracted by 2 authors and study quality was assessed by 2 other authors. DATA SYNTHESIS: Overall, 60% (1162/1948 cases) of primary tumors showed absent or markedly reduced Fhit protein expression in cancer cells. Studies of preneoplastic lesions or early-stage cancer showed absence or marked reduction of Fhit protein expression in 0% to 93% of samples (overall, 31% [127/408 cases]). Preclinical studies using 26 cancer-derived cell lines from human lung, head and neck, esophageal, gastric, cervical, pancreatic, and kidney cancers, showed that reintroduction of FHIT resulted in inhibition of in vitro tumor cell growth or of in vivo tumorigenicity in 17 (57%) of 30 cell line experiments. Model systems for human preventive cancer therapy suggested that oral introduction of viral vector-mediated FHIT into Fhit-deficient mice may prevent carcinogen-induced tumor development in some cases. CONCLUSION: These findings show that FHIT gene therapy may potentially be clinically useful for treatment of cancer and also prevention of carcinogen-induced tumor development, suggesting a rationale for further research involving FHIT introduction. 相似文献
42.
Thomas Powles Michael B. Atkins Bernard Escudier Robert J. Motzer Brian I. Rini Lawrence Fong Richard W. Joseph Sumanta K. Pal Mario Sznol John Hainsworth Walter M. Stadler Thomas E. Hutson Alain Ravaud Sergio Bracarda Cristina Suarez Toni K. Choueiri James Reeves Allen Cohn David F. McDermott 《European urology》2021,79(5):665-673
BackgroundThe use of immune checkpoint inhibitors combined with vascular endothelial growth factor (VEGF)-targeted therapy as second-line treatment for metastatic clear cell renal cancer (mRCC) has not been evaluated prospectively.ObjectiveTo evaluate the efficacy and safety of atezolizumab + bevacizumab following disease progression on atezolizumab or sunitinib monotherapy in patients with mRCC.Design, setting, and participantsIMmotion150 was a multicenter, randomized, open-label, phase 2 study of patients with untreated mRCC. Patients randomized to the atezolizumab or sunitinib arm who had investigator-assessed progression as per RECIST 1.1 could be treated with second-line atezolizumab + bevacizumab.InterventionPatients received atezolizumab 1200 mg intravenously (IV) plus bevacizumab 15 mg/kg IV every 3 wk following disease progression on either atezolizumab or sunitinib monotherapy.Outcome measurements and statistical analysisThe secondary endpoints analyzed during the second-line part of IMmotion150 included objective response rate (ORR), progression-free survival (PFS), and safety. PFS was examined using Kaplan-Meier methods.Results and limitationsFifty-nine patients in the atezolizumab arm and 78 in the sunitinib arm were eligible, and 103 initiated second-line atezolizumab + bevacizumab (atezolizumab arm, n = 44; sunitinib arm, n = 59). ORR (95% confidence interval [CI]) was 27% (19–37%). The median PFS (95% CI) from the start of second line was 8.7 (5.6–13.7) mo. The median event follow-up duration was 19.4 (12.9–21.9) mo among the 25 patients without a PFS event. Eighty-six (83%) patients had treatment-related adverse events; 31 of 103 (30%) had grade 3/4 events. Limitations were the small sample size and selection for progressors.ConclusionsThe atezolizumab + bevacizumab combination had activity and was tolerable in patients with progression on atezolizumab or sunitinib. Further studies are needed to investigate sequencing strategies in mRCC.Patient summaryPatients with advanced kidney cancer whose disease had worsened during treatment with atezolizumab or sunitinib began second-line treatment with atezolizumab + bevacizumab. Tumors shrank in more than one-quarter of patients treated with this combination, and side effects were manageable. 相似文献
43.
44.
Fong Zhi Ven Sekigami Yurie Qadan Motaz Fernandez-del Castillo Carlos Warshaw Andrew L. Lillemoe Keith D. Ferrone Cristina R. 《Annals of surgical oncology》2021,28(8):4216-4224
Annals of Surgical Oncology - Long-term pancreatoduodenectomy (PD) survivors have previously reported favorable quality of life (QoL). However, there has been a paucity of studies utilizing... 相似文献
45.
JS Tsang Chi Chung Foo Jeremy Yip Hok Kwok Choi Wai Lun Law Oswens Siu Hung Lo 《The surgeon》2021,19(3):150-155
IntroductionThe difference in outcome between right (RCD) and left colonic diverticulitis (LCD) is not well established. The aim of this study was to analyse the presentation and surgical outcome of RCD versus left-sided disease following emergency surgery.MethodWe conducted a retrospective review of patients presenting with acute diverticulitis over a 10-year period from 2004 to 2014 to a tertiary unit. Patient demographics, Hinchey classification, need for emergency surgery, perioperative outcome and recurrence were evaluated.ResultsIn total 360 patients presented with acute diverticulitis, 218 (61%) were right-sided and 142 (39%) were left-sided. The mean age (57 yrs vs 68 yrs) and median length of stay (4 days vs 5 days) were significantly less in RCD (p < 0.001). The need for emergency surgery was similar between RCD and LCD (30.7% vs 23.2%, p = 0.12). Sixty-seven (31%) patients with RCD required emergency surgery, 42 (62.7%) of these were based on a presumptive diagnosis of appendicitis and underwent laparoscopic appendicectomy only. Operative morbidity (10.4% vs 51.5%, p < 0.001) and mortality were significantly higher in LCD (1.5% v 15.2%, p = 0.007). Subgroup analysis of non-appendicectomy, RCD patients, showed LCD were more likely to require surgery (11.5% vs 23.2%, p = 0.003). There was no difference in recurrence (p = 0.6).ConclusionRight colonic diverticulitis patients are younger and disease course is more benign compared to LCD. Presentation can be confused with appendicitis without proper imaging. In the rare cases where emergency surgery is required, RCD is associated with a lower operative morbidity and mortality compared to left-sided disease. 相似文献
46.
47.
48.
7例尿毒症贫血患者在自发急性缺氧状态下,其血清红细胞生成素(EPO)浓度显著提高(平均7倍),且与PO2呈负相关。缺氧状态纠正后血清EPO浓度下降。提示尿毒症贫血患者的EPO氧依赖调控系统功能尚存在,但处于不敏感的低调状态。进一步了解其机遇,则可能通过促进内源性EPO的生成,有助于悄毒症贫血的治疗。 相似文献
49.
50.
Investigation of nimodipine pharmacokinetics in Chinese patients with acute subarachnoid haemorrhage
C. R. Kumana M. Kou Y. L. Yu K. Y. Fong C. F. Fung C. M. Chang W. Mück I. J. Lauder 《European journal of clinical pharmacology》1993,45(4):363-366
Summary Nimodipine pharmacokinetics was investigated in 12 Chinese patients with acute subarachnoid haemorrhage receiving an IV infusion of 1.6 or 2 mg/h (based on estimated body weight) for 10 days. Peripheral venous blood samples were collected for up to 4 days and plasma nimodipine was assayed by GC/ECD. The mean value was taken as the steady state concentration (Css) and Clearance (CL) (hourly dose/Css) was calculated. Eight survivors were given oral nimodipine (60 or 90 mg) every 6h (based on body weight), blood was sampled over 6 h and the plasma nimodipine level determined. The values for Css, CL and CL·kg–1 were 33.5 g·l–1, 58 l·h–1 and 1.0 l·h–1·kg–1 respectively; in survivors receiving the drug orally, bioavailability of the 30 mg tablet was 9%. In one very sick patient given crushed tablets by naso-gastric tube, the AUC was very low; in vitro studies indicated that adsorption of nimodipine by the tubing was unlikely to have been the cause.The pharmacokinetic findings in Chinese patients are comparable to previously reported values in Caucasians. 相似文献